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1022MP-167 National Trends in the Care of Patients With Heart 
Failure, 1999-2001: Results From the CMS National 
Heart Failure Project 
Frederick A. Masoudl, Beth R. Stevens, Joanne M. Foody, Edward P. Havranek, Harlan 
M. Krumholz, Diana L. Ordin, Denver Health Medical Center, Denver, CO, Colorado 
Foundation for Medical Care, Aurora, CO 
Background: Changes in national patterns of quality of care for patients with heart fail- 
ure have not been reported previously. Our goal was to characterize recent trends in 
heart failure care in the US over the last three years. 
Methods: We studied the care of Medicare beneficiaries hospitalized nationwide with the 
principal discharge diagnosis of heart failure between two 12-month time periods in 
1998-99 and 2000-01 with data from the CMS-sponsored National Heart Failure Project. 
We assessed changes in rates of two guideline-based quality indicators: documentation 
of the assessment of left ventricular systolic function (LVSF) assessed and the prescrip- 
tion of ACE-inhibitors at hospital discharge for patients with left ventricular systolic dys- 
function (LVSD) without ACE contraindications. 
Results: While documentation of LVSF assessment increased from 67% to 71% 
(p<O.OOl) between the sampling periods, the prescription of ACE-inhibitors for eligible 
patients declined from 69% to 67% (p=O.O06). Indicator rates for patient subsets are pre- 
sented in the Table. 
Conclusions: In spite of the longstanding availability of strong clinical evidence and the 
proliferation of practice guidelines for the treatment of heart failure, significant gaps in the 
quality of care for patients with hearl failure persist nationwide, and improvements in 
care, where they exist, have been modest. There is an ongoing need for the study of the 
root causes of sub-optimal care and for initiatives in improving heart failure care. 
Female Male White Non-white 65-79 years 280 years 
LVEF 1998-99 65% 69% 67% 66% 70% 63% 
LVEF 2000.02 70% 74% 67% 71% 74% 68% 
ACE 1998-99 67% 70% 68% 72% 69% 68% 
ACE 2000.01 67% 67% 66% 69% 68% 66% 
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1022MP-169 Influence of Guidelines and Results From Major Clinical 
Trials on Medical Practice: Findings From the Global 
Registry of Acute Coronary Events (GRACE) 
Keith A. Fox, Shaun G. Goodman, Fred A. Anderson, Christopher B. Granger, Mauro 
Moscucci, Marcus D. Flather, Frederick A. Spencer, Andrzej Budaj, Omar H. Dabbous, 
Joel M. Gore, on behalf of the GRACE Investigators. Royal Infirmary of Edinburgh, 
Edinburgh, United Kingdom, Duke University Medical Center, Durham, NC 
Background: The extent to which key clinical trials and practice guidelines influence the 
rate of uptake into clinical practice remains uncertain. Hospital characteristics and geo- 
graphic factors may also have a profound influence. 
Methods: GRACE provides data on the uptake of therapies into practice across diverse 
but geographically representative communities. We hypothesized that availability of local 
facilities may profoundly influence the rate of uptake. 
Results: 
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Aspirin was widely adopted; use of LMWH, GP Ilb/lila, statin, ACE inhibitor and PCI 
increased. Increasing use of statins in the acute hospital phase and use of LMWH and 
GP Ilb/lllas in STEMI occurred in advance of published evidence/guidelines (Sept 00). 
Marked discrepancies exist according to teaching status (or not) in use of GPllb/llla for 
NSTEMI: 29% vs 18 % (not). Use of PCI was almost 7 fold higher in hospitals wtth on-site 
PCI facilities: 41% vs 7% (not). Geographic differences exist for use of PCI in NSTEMI: 
39% US, 34-36% Europe and S America, and 24% Australia/ NZ /Canada with 
corresponding usage of GPllb/lllas. Highest use of LMWH was in Australia/ NZi Canada 
(74%) and lowest in US (28%). 
Conclusion: No clear relationship is apparent between publication of AHA4ACC and 
ESC auidellnes and rate of uptake into practice. Hosuital, aeographic and other 
characteristics appear to havk a much &a marked influe&ebn~uptake of evidence- 
based therapies into clinical practkx?. 
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1022MP-170 Racial Differences in Acute Reperfueion Therapy Use in 
Patients Hospitalized With Acute Myocardial Infarction: 
A Regional Phenomenon 
Saif S. Rathore, Paul D. Frederick, Nathan R. Every, Hal V. Barron, Harlan M. Krumholz. 
Yale University School of Medicine, New Haven, CT, Genentech, Inc., South San 
Francisco, CA 
Background: Racial differences in acute reperfusion therapy (RT) use among patients 
hospitalized with acute myocardial infarction have been previously reported as national 
phenomenon. However, it is unclear whether racial differences in treatment vary by 
region. 
Methods: We used data from the National Registry of Myocardial Infarction-2 and -3, a 
cohort of patients hospitalized with acute myocardial Infarction in the United States 
between 1994 and 2000, to determine if racial differences in the use of RTvaried by geo- 
graphic region. Patients eligible for RT with no clinical contraindications to treatment 
(n-204,230) were classtfied by US Census region (Northeast, Midwest, South, and 
West) based on the lwation of their treating hospital and evaluated for the use of RT on 
admission. Racial differences in RT use were evaluated nationwide and by Census 
region. Multivariable logistic regression analyses were conducted using a patient racei 
region Interaction term to test if racial differences in RT use varied by region and ware 
independent of clinical and hospital characteristics. 
Results: Black patients had lower rates of RT use than white patients nabonwide (66.5% 
vs. 69.9%, P<O.OOl). Racial differences in RT use varied by Census region. Black 
patients in the Northeast had higher RT rates than whites (67.9% vs. 65.3%, P=O.O32). 
There were no racial differences in RT use in the Midwest (68.3% black vs. 69.0% white, 
P=O.39) or West (70.7% black vs. 72.6% white, P=O.l I). Lower rates of RT use ln black 
patients compared with white patients were only observed in the South (64.5% vs. 
71.7%. P<O.O011. Reaional variabons in racial differences in RT use persisted after multi- 
variable adjustment for patient and hospital characteristics (p<O.OOl for race’Census 
region interaction). 
Conclusions: Although black patients hospitalwad with acute myccardial infarction have 
lower RT rates than white patients overall, this racial difference occurs exclusively in 
patients treated in the South. There are no significant or substantial racial differences in 
RT use among patients treated in the Northeast, Midwest, or West. 
